Medochemie: Sole Holder of EU Marketing Authorization for Praziquantel 600mg
Medochemie Ltd, based in Cyprus, is currently the only pharmaceutical company in the European Union to hold a marketing authorization for Praziquantel 600mg, supplying this vital medication to European markets.
A Critical Medication for Public Health
Praziquantel has been approved and used in Europe for decades, but its availability has been severely restricted in recent years due to market shortages and the discontinuation of production by the original manufacturer. This development, which was communicated in advance to European authorities, has led to a pan-European shortage.
In response to the needs of healthcare systems and patients, Medochemie produces and distributes Praziquantel, contributing to meeting the needs of all 27 EU member states.
First Shipment to Greece
The first shipment of the product was made last week to Greece to cover patient needs for 2026, with further shipments to other EU member states expected to follow after completing the necessary import licensing procedures.
Praziquantel is a first-line, broad-spectrum treatment for infections caused by trematode parasites and has a well-documented safety profile. Its contribution to public health is particularly significant globally.
The drug is effective against most trematode parasites that infect humans, including Schistosoma haematobium, Schistosoma mansoni, Schistosoma japonicum, and Schistosoma intercalatum. It is also used to treat infections caused by other types of parasites, such as Clonorchis sinensis and Opisthorchis viverrini, as well as Paragonimus westermani.
Praziquantel is widely used in mass treatment programs for the control of schistosomiasis in endemic areas and is included in the World Health Organization's List of Essential Medicines for 2025, highlighting its importance for global public health.